These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

162 related articles for article (PubMed ID: 37332746)

  • 1. Historical eye on IPF: a cohort study redefining the mortality scenario.
    Tomassetti S; Ravaglia C; Piciucchi S; Ryu J; Wells A; Donati L; Dubini A; Klersy C; Luzzi V; Gori L; Rosi E; Lavorini F; Poletti V
    Front Med (Lausanne); 2023; 10():1151922. PubMed ID: 37332746
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Possible value of antifibrotic drugs in patients with progressive fibrosing non-IPF interstitial lung diseases.
    Torrisi SE; Kahn N; Wälscher J; Sarmand N; Polke M; Lars K; Eichinger M; Heussel CP; Palmucci S; Sambataro FM; Sambataro G; Sambataro D; Vancheri C; Kreuter M
    BMC Pulm Med; 2019 Nov; 19(1):213. PubMed ID: 31718637
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Antifibrotic therapies reduce mortality and hospitalization among Medicare beneficiaries with idiopathic pulmonary fibrosis.
    Mooney J; Reddy SR; Chang E; Broder MS; Gokhale S; Corral M
    J Manag Care Spec Pharm; 2021 Dec; 27(12):1724-1733. PubMed ID: 34818092
    [No Abstract]   [Full Text] [Related]  

  • 4. Switching antifibrotics in patients with idiopathic pulmonary fibrosis: a multi-center retrospective cohort study.
    Suzuki Y; Mori K; Aono Y; Kono M; Hasegawa H; Yokomura K; Naoi H; Hozumi H; Karayama M; Furuhashi K; Enomoto N; Fujisawa T; Nakamura Y; Inui N; Nakamura H; Suda T
    BMC Pulm Med; 2021 Jul; 21(1):221. PubMed ID: 34247593
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Real-World Study Analysing Progression and Survival of Patients with Idiopathic Pulmonary Fibrosis with Preserved Lung Function on Antifibrotic Treatment.
    Noor S; Nawaz S; Chaudhuri N
    Adv Ther; 2021 Jan; 38(1):268-277. PubMed ID: 33098554
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Outcomes of patients with advanced idiopathic pulmonary fibrosis treated with nintedanib or pirfenidone in a real-world multicentre cohort.
    Durheim MT; Bendstrup E; Carlson L; Sutinen EM; Hyldgaard C; Kalafatis D; Myllärniemi M; Sköld CM; Sjåheim T
    Respirology; 2021 Oct; 26(10):982-988. PubMed ID: 34291523
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Impact of reduction in antifibrotic treatment on mortality in idiopathic pulmonary fibrosis.
    Porse S; Hoyer N; Shaker SB
    Respir Med; 2022; 204():107015. PubMed ID: 36347111
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effect of Antifibrotic Therapy on Survival in Patients With Idiopathic Pulmonary Fibrosis.
    de Andrade JA; Neely ML; Hellkamp AS; Culver DA; Kim HJ; Liesching T; Lobo LJ; Ramaswamy M; Safdar Z; Bender S; Conoscenti CS; Leonard TB; Palmer SM; Snyder LD;
    Clin Ther; 2023 Apr; 45(4):306-315. PubMed ID: 36997445
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Efficacy of antifibrotic drugs, nintedanib and pirfenidone, in treatment of progressive pulmonary fibrosis in both idiopathic pulmonary fibrosis (IPF) and non-IPF: a systematic review and meta-analysis.
    Finnerty JP; Ponnuswamy A; Dutta P; Abdelaziz A; Kamil H
    BMC Pulm Med; 2021 Dec; 21(1):411. PubMed ID: 34895203
    [TBL] [Abstract][Full Text] [Related]  

  • 10.
    Doubkova M; Kriegova E; Littnerova S; Schneiderova P; Sterclova M; Bartos V; Plackova M; Zurkova M; Bittenglova R; Lostaková V; Siskova L; Lisa P; Suldova H; Doubek M; Psikalova J; Snizek T; Musilova P; Vasakova M
    Ther Adv Respir Dis; 2021; 15():17534666211042529. PubMed ID: 34515605
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Tolerability and efficacy of second-line antifibrotics in patients with idiopathic pulmonary fibrosis.
    Cilli A; Uzer F; Sevinç C; Coşkun F; Ursavaş A; Öner Ş; Kose F
    Pulm Pharmacol Ther; 2021 Dec; 71():102099. PubMed ID: 34793978
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Longitudinal Changes in Clinical Features, Management, and Outcomes of Idiopathic Pulmonary Fibrosis. A Nationwide Cohort Study.
    Moon SW; Kim SY; Chung MP; Yoo H; Jeong SH; Kim DS; Song JW; Lee HL; Choi SM; Kim YW; Kim YH; Park CS; Park SW; Park JS; Jegal Y; Lee J; Uh ST; Kim TH; Lee JH; Kim YH; Shin B; Lee HK; Yang SH; Lee H; Kim SH; Lee EJ; Choi HS; Shin H; Park YB; Shin JW; Park MS
    Ann Am Thorac Soc; 2021 May; 18(5):780-787. PubMed ID: 33270528
    [No Abstract]   [Full Text] [Related]  

  • 13. Impact of Lung Biopsy Information on Treatment Strategy of Patients with Interstitial Lung Diseases.
    Tomassetti S; Ravaglia C; Puglisi S; Ryu JH; Colby TV; Cavazza A; Wells AU; Pavone M; Vancheri C; Lavorini F; Matucci-Cerinic M; Rosi E; Luzzi V; Gori L; Rossi G; Donati L; Dubini A; Piciucchi S; Poletti V
    Ann Am Thorac Soc; 2022 May; 19(5):737-745. PubMed ID: 34739359
    [No Abstract]   [Full Text] [Related]  

  • 14. Pirfenidone vs. nintedanib in patients with idiopathic pulmonary fibrosis: a retrospective cohort study.
    Marijic P; Schwarzkopf L; Schwettmann L; Ruhnke T; Trudzinski F; Kreuter M
    Respir Res; 2021 Oct; 22(1):268. PubMed ID: 34666765
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Mortality and Respiratory-Related Hospitalizations in Idiopathic Pulmonary Fibrosis Not Treated With Antifibrotics.
    Cottin V; Spagnolo P; Bonniaud P; Nolin M; Dalon F; Kirchgässler KU; Kamath TV; Van Ganse E; Belhassen M
    Front Med (Lausanne); 2021; 8():802989. PubMed ID: 35004781
    [No Abstract]   [Full Text] [Related]  

  • 16. Disease progression across the spectrum of idiopathic pulmonary fibrosis: A multicentre study.
    Sgalla G; Lo Greco E; Calvello M; Varone F; Iovene B; Cerri S; Donatelli P; Vancheri A; Pavone M; Luppi F; Vancheri C; Richeldi L
    Respirology; 2020 Nov; 25(11):1144-1151. PubMed ID: 32190952
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Incidence of acute exacerbation of idiopathic pulmonary fibrosis in patients receiving antifibrotic agents: Real-world experience.
    Isshiki T; Sakamoto S; Yamasaki A; Shimizu H; Miyoshi S; Nakamura Y; Homma S; Kishi K
    Respir Med; 2021 Oct; 187():106551. PubMed ID: 34343721
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pirfenidone in patients with progressive fibrotic interstitial lung diseases other than idiopathic pulmonary fibrosis (RELIEF): a double-blind, randomised, placebo-controlled, phase 2b trial.
    Behr J; Prasse A; Kreuter M; Johow J; Rabe KF; Bonella F; Bonnet R; Grohe C; Held M; Wilkens H; Hammerl P; Koschel D; Blaas S; Wirtz H; Ficker JH; Neumeister W; Schönfeld N; Claussen M; Kneidinger N; Frankenberger M; Hummler S; Kahn N; Tello S; Freise J; Welte T; Neuser P; Günther A;
    Lancet Respir Med; 2021 May; 9(5):476-486. PubMed ID: 33798455
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Differential Discontinuation Profiles between Pirfenidone and Nintedanib in Patients with Idiopathic Pulmonary Fibrosis.
    Takehara K; Koga Y; Hachisu Y; Utsugi M; Sawada Y; Saito Y; Yoshimi S; Yatomi M; Shin Y; Wakamatsu I; Umetsu K; Kouno S; Nakagawa J; Sunaga N; Maeno T; Hisada T
    Cells; 2022 Jan; 11(1):. PubMed ID: 35011705
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effect of antifibrotic therapy in patients with idiopathic pulmonary fibrosis undergoing lung transplant in the peri and post-operative period.
    Dorey-Stein ZL; Shapiro W; Zhao H; Cordova FC; Criner GJ; Galli JA
    Respir Med; 2021 Dec; 190():106599. PubMed ID: 34788735
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.